Bibliographic Details
| Title: |
Orphan designation: Amatuximab for the treatment of malignant mesothelioma, 16 Jan 2014, Positive (EU/3/13/1222). |
| Source: |
Chemical Business NewsBase (UK), October 12, 2018, 1pp |
| Abstract: |
On 16 Jan 2014, orphan designation (EU/3/13/1222) was granted by the European Commission to Eisai Europe Limited, United Kingdom, for amatuximab for the treatment of malignant mesothelioma. The sponsorship was transferred to Eisai GmbH, Germany, in Sep 2018. Original Source: EMA: EMA/COMP/7038/2014: Public summary of opinion on orphan designation: Amatuximab for the treatment of malignant mesothelioma; https://www.ema.europa.eu/documents/orphan-designation/eu/3/13/1222-public-summary-opinion-orphan-designation-amatuximab-treatment-malignant-mesothelioma_en.pdf; 21 Mar 2014... |
| Database: |
NewsBank |
